Compare GE Vernova Inc (GEV) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Sanofi SA — how do they compare? GE Vernova Inc trades at $1,003.8 (market cap $266.16B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: GE Vernova Inc is far larger — about 2.8× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Sanofi SA for 94 Days on average.
| GEV | SNY | |
|---|---|---|
Market Cap | $266.16B | $95.18B |
Volume | 2,324,165 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $1.17K | $52.34 |
52-Week Low | $547.96 | $39.51 |
Typical Hold Time | 36 Days | 94 Days |
Enterprise Value | $255.83B | $114.48B |
Dividend Yield | 0.2% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $1,004.73, up 0.77% with strong bullish technical momentum. The stock shows exceptional profitability with 23.04% net margins and 91.48% ROE, though valuation appears elevated with P/E of 28.65. Recent Q2 2026 earnings missed expectations, but Q1 and Q4 2025 results significantly beat forecasts. The company secured the first US construction permit for its BWRX-300 SMR, strengthening its nuclear pipeline amid growing AI-driven power demand.
Outlook remains positive with 75.86% analyst buy ratings and $1,270 consensus price target representing 26% upside. Key risks include execution challenges in wind segment and valuation concerns. Strong backlog growth to $176 billion and AI power demand create substantial growth runway, though investors should monitor margin expansion and competitive pressures.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
